Skip to main content

Table 2 Parameter used in the base-case

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Type of parameter Base Case value References
Demographics
Population 60,795,612 [18]
Male in the health plan (% of total) 48.5% [17]
Paediatric in the health plan (% of total) 11.9% [17]
Annual population growth 0.5% [18]
Paediatric weight (Kg) 18.5 [21]
Adult weight (Kg) 70.6 [22]
Epidemiology
HA prevalence in male 12.7 per 100,000 [16]
Severity distribution of the disease
 Mild 39.7% [16]
 Moderate 14.1%
 Severe 46.2%
Patients without inhibitors
 Mild 99.1% [16]
 Moderate 96.3%
 Severe 81.6%
Treatment regimen among adults
 On demand 42.8% [16]
 Prophylaxis 55.2%
Treatment regimen among paediatrics
 On demand 0% Assumption based on the opinion of clinical experts
 Prophylaxis 100%
Costs
rFVIIIFc unit cost (€/IU) 0.72 [25]
Advate® unit cost (€/IU) 0.65 [25]
Kogenate® unit cost (€/IU) 0.69 [25]
Refacto® unit cost (€/IU) 0.69 [25]
Helixate® unit cost (€/IU) 0.69 [25]
Recombinate® unit cost (€/IU) 0.60 [25]
Plasma-derived unit cost (€/IU) 0.60 [25]
\